Grufity logoGrufity logo
StocksFundsSearch Filings

AN2 Therapeutics, Inc. Stock Research

ANTX

5.71USD-0.60(-9.51%)Market Closed

Market Summary

USD5.71-0.60
Market Closed
-9.51%

ANTX Alerts

ANTX Stock Price

ANTX RSI Chart

ANTX Valuation

Market Cap

111.7M

Price/Earnings (Trailing)

-2.73

Price/Sales (Trailing)

82.65

Price/Free Cashflow

-3.34

ANTX Price/Sales (Trailing)

ANTX Profitability

Return on Equity

-36.77%

Return on Assets

-35.29%

Free Cashflow Yield

-29.97%

ANTX Fundamentals

ANTX Revenue

Revenue (TTM)

1.4M

Revenue Y/Y

2.2K%

Revenue Q/Q

35.19%

ANTX Earnings

Earnings (TTM)

-41.0M

Earnings Y/Y

-56.95%

Earnings Q/Q

-4.44%

Price Action

52 Week Range

4.8722.49
(Low)(High)

Last 7 days

-22.3%

Last 30 days

-33.8%

Last 90 days

-53.1%

Trailing 12 Months

-48.7%

ANTX Financial Health

Current Ratio

24.21

ANTX Investor Care

Shares Dilution (1Y)

610.64%

Diluted EPS (TTM)

-2.79

Financials for AN2 Therapeutics

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue80.6%1,35174830794.0069.00
Operating Expenses13.1%42,26237,38032,54227,20721,574
  S&GA Expenses18.0%12,75110,8099,0546,3174,668
  R&D Expenses13.7%28,51125,07122,98820,14016,156
Net Income-11.7%-40,956-36,659-32,263-27,150-21,543
Net Income Margin54.3%-40.38*-88.28*-301.48*-415*-
Free Cahsflow-22.8%-34,432-28,037-23,998-13,600-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-6.8%10311012012165.00
  Current Assets-8.1%99.0010711712060.00
    Cash Equivalents-5.5%27.0029.0041.0083.0012.00
Liabilities62.1%7.004.004.005.003.00
  Current Liabilities62.1%7.004.004.005.003.00
Shareholder's Equity-9.7%95.00106116115-47.41
  Retained Earnings-15.2%-89.72-77.88-66.54-56.42-47.38
  Additional Paid-In Capital0.8%185184183172-
Shares Outstanding0%19.0019.0019.0019.003.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations3.9%-33.46-34.82-30.02-25.68-20.48
  Share Based Compensation31.0%4.003.002.001.001.00
Cashflow From Investing-0.9%-21.77-21.58-26.2518.00-50.02
Cashflow From Financing1.4%70.0069.0069.0062.0079.00

Risks for ANTX

What is the probability of a big loss on ANTX?

85.7%


Probability that AN2 Therapeutics stock will be more than 20% underwater in next one year

85.7%


Probability that AN2 Therapeutics stock will be more than 30% underwater in next one year.

85.7%


Probability that AN2 Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ANTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AN2 Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ANTX

Cumulative Returns on ANTX

Which funds bought or sold ANTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-22
American Trust
added
3.27
-34,953
435,440
0.03%
2023-05-22
Arete Wealth Advisors, LLC
added
0.14
-375,148,000
337,000
0.03%
2023-05-22
Raleigh Capital Management Inc.
added
313
198,680
272,190
0.14%
2023-05-22
AMERIPRISE FINANCIAL INC
added
12.92
18,688,300
1,664,420,000
0.55%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
1,655,000
0.07%
2023-05-22
PUTNAM INVESTMENTS LLC
added
2.62
-37,329,300
428,357,000
0.69%
2023-05-19
Trivant Custom Portfolio Group, LLC
new
-
2,989,680
2,989,680
2.14%
2023-05-19
Coppell Advisory Solutions LLC
sold off
-100
-11,798
-
-%
2023-05-18
COURIER CAPITAL LLC
added
3.57
-20,573
266,690
0.03%
2023-05-18
JPMORGAN CHASE & CO
added
35.87
24,000
84,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying ANTX calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ANTX
No. of Funds

AN2 Therapeutics News

InvestorsObserver
Should You Buy AN2 Therapeutics Inc (ANTX) Stock on Wednesday?.
InvestorsObserver,
6 days ago
Investment U

Schedule 13G FIlings of AN2 Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
ra capital management, l.p.
19.5%
3,773,517
SC 13G/A
Feb 14, 2023
citadel advisors llc
6.9%
6
SC 13G/A
Feb 14, 2023
biotechnology value fund l p
4.4%
846,993
SC 13G/A
Feb 13, 2023
pfizer inc
7.02%
0
SC 13G
Feb 13, 2023
brii biosciences ltd
5.4%
1,048,479
SC 13G

ANTX Fair Value

Recent SEC filings of AN2 Therapeutics

View All Filings
Date Filed Form Type Document
May 15, 2023
4
Insider Trading
May 11, 2023
10-Q
Quarterly Report
May 11, 2023
8-K
Current Report
Apr 26, 2023
ARS
ARS
Apr 26, 2023
DEF 14A
DEF 14A
Apr 26, 2023
DEFA14A
DEFA14A
Apr 14, 2023
424B5
Prospectus Filed
Apr 13, 2023
EFFECT
EFFECT
Apr 11, 2023
CORRESP
CORRESP
Apr 10, 2023
UPLOAD
UPLOAD

Latest Insider Trading transactions for ANTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-15
Easom Eric
bought
53,770
5.377
10,000
chief executive officer
2022-11-14
Easom Eric
sold
-345
15.04
-23.00
chief executive officer
2022-11-10
Easom Eric
sold
-67,628
15.3248
-4,413
chief executive officer
2022-11-09
Easom Eric
sold
-157,847
15.6114
-10,111
chief executive officer
2022-11-08
Easom Eric
sold
-109,947
15.5842
-7,055
chief executive officer
2022-11-07
Easom Eric
sold
-195,741
16.0404
-12,203
chief executive officer
2022-11-04
Easom Eric
sold
-139,474
15.7991
-8,828
chief executive officer
2022-11-03
Easom Eric
sold
-223,058
15.7472
-14,165
chief executive officer
2022-11-02
Easom Eric
sold
-23,262
15.0664
-1,544
chief executive officer
2022-10-31
Easom Eric
sold
-41,362
15.3879
-2,688
chief executive officer

1–10 of 42

Eric Easom
20
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

ANTX Income Statement

2023-03-31
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:  
Research and development expense related party$ 11,985$ 5,633
General and administrative4,0542,050
Total operating expenses16,0397,683
Loss from operations(16,039)(7,683)
Other income, net71628
Net loss(15,323)(7,655)
Accretion to redemption value and cumulative dividends on preferred stock (1,820)
Net loss attributable to common stockholders$ (15,323)$ (9,475)
Net loss per share attributable to common stockholders, basic$ (0.79)$ (2.98)
Net loss per share attributable to common stockholders, diluted$ (0.79)$ (2.98)
Weighted-average number of shares used in computing net loss per share, basic19,385,6463,180,717
Weighted-average number of shares used in computing net loss per share, diluted19,385,6463,180,717
Other comprehensive loss:  
Unrealized gain (loss) on investments$ 199$ (131)
Comprehensive loss$ (15,124)$ (7,786)

ANTX Balance Sheet

2023-03-31
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 26,709$ 27,219
Short-term investments61,80668,840
Prepaid expenses and other current assets1,7672,509
Right-of-use asset, net3453
Total current assets90,31698,621
Deferred offering costs48 
Long-term investments 3,219
Other assets, long-term720720
Total assets91,084102,560
Current liabilities:  
Accounts payable3,5452,122
Accrued compensation7412,168
Accrued liabilities4,2412,837
Operating lease liabilities3453
Options subject to repurchase, short-term56
Total current liabilities8,5667,186
Options subject to repurchase, long-term12
Total liabilities8,5677,188
Commitments and contingencies (Note 7)
Stockholders' equity:  
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2023 and December 31, 2022; 19,426,452 and 19,402,658 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Additional paid-in capital187,738185,469
Accumulated other comprehensive loss(175)(374)
Accumulated deficit(105,046)(89,723)
Total stockholders' equity82,51795,372
Total liabilities, redeemable convertible preferred stock, and stockholders' equity$ 91,084$ 102,560